ADSKAutodesk

On May 29, 2026, Andrew Anagnost, our President and Chief Executive Officer terminated his pre-existing Rule 10b5-1 trading arrangement adopted on August 29, 2025 providing for the sale from time to time of an aggregate of up to 93,097 shares of our common stock. On June 23, 2026, Mr. Anagnost, adopted a new Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 66,394 shares of our common stock. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until July 1, 2027, or earlier if all transactions under the trading arrangement are completed.

On March 26, 2026, Steve Blum, our Chief Operating Officer, adopted a new Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 19,894 shares of our common stock. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until March 26, 2027, or earlier if all transactions under the trading arrangement are completed.

On August 29, 2025, Andrew Anagnost, our President and Chief Executive Officer, adopted a new Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 93,097 shares of our common stock. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until September 1, 2026, or earlier if all transactions under the trading arrangement are completed.

On June 5, 2025, Steve Blum, our Chief Operating Officer, adopted a new Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 22,420 shares of our common stock. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until December 12, 2025, or earlier if all transactions under the trading arrangement are completed.

On March 11, 2025, Rebecca Pearce, our Chief People Officer, adopted a new Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 34,683 shares of our common stock. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until May 29, 2026, or earlier if all transactions under the trading arrangement are completed.

On December 4, 2024, Dr. Ayanna Howard, one of our directors, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 8,170 shares of our common stock. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until December 4, 2026, or earlier if all transactions under the trading arrangement are completed.

On October 3, 2024, Stephen Hope, our SVP, Finance & Chief Accounting Officer, adopted a new Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 7,088 shares of our common stock. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until April 11, 2025, or earlier if all transactions under the trading arrangement are completed. Prior to entering into the new Rule 10b5-1 trading arrangement in October 2024, Mr. Hope’s previous Rule 10b5-1 trading arrangement expired according to its terms because all the transactions under the arrangement were completed.

On September 4, 2024, Lorrie Norrington, one of our directors, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 3,556 shares of our common stock. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until March 4, 2025, or earlier if all transactions under the trading arrangement are completed.

Securities Trading Plans of Directors and Executive Officers During our last fiscal quarter ended July 31, 2024, the following director(s) and officer(s), as defined in Rule 16a-1(f), adopted a “Rule 10b5-1 trading arrangement” as defined in Regulation S-K Item 408, as follows: On July 1, 2024, Stephen Hope, our SVP, Finance & Chief Accounting Officer, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 718 shares of our common stock. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until January 2, 2025, or earlier if all transactions under the trading arrangement are completed.

On December 19, 2023, Steve Blum, our Chief Operating Officer, on behalf of the BLUM FAM DECL. TR UAD 4/20/06, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 66,740 shares of our common stock. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until November 29, 2024, or earlier if all transactions under the trading arrangement are completed.

On September 13, 2023, Mary McDowell, one of our Directors, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 14,100 shares of our common stock. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until December 13, 2024, or earlier if all transactions under the trading arrangement are completed.

On June 30, 2023, Lorrie Norrington, one of our Directors, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 2,148 shares of our common stock. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until December 29, 2023, or earlier if all transactions under the trading arrangement are completed.

On May 26, 2023, Dr. Andrew Anagnost, our CEO, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 112,061 shares of our common stock, net of shares withheld for taxes. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until April 26, 2024, or earlier if all transactions under the trading arrangement are completed.

On May 26, 2023, Deborah L. Clifford, our CFO, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 41,149 shares of our common stock, net of shares withheld for taxes. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until April 12, 2024, or earlier if all transactions under the trading arrangement are completed.